Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy - A follow-up study

Radiotherapy and Oncology

Volumn 90, Issue 3, 2009, Pages 408-412

  Zechmann, Christian M ^a   Aftab, Khurram ^a   Didinger, Bernd ^b   Giesel, Frederik L ^a   Zamecnik, Patrik ^a   Thieke, Christian ^a   Fütterer, Jurgen J ^c   Kopp Schneider, Annette ^a   Kauczor, Hans Ulrich ^a   Delorme, Stefan ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen deprivation; IMRT; Prostate cancer; Radiation induced effects; Volume change

Indexed keywords

BICALUTAMIDE; BUSERELIN; CYPROTERONE; FLUTAMIDE; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MALE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; TREATMENT DURATION; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; PROSTATE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 61349165494     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.09.006     Document Type: Article

References (30)

1. Forman J.D., Kumar R., Haas G., et al. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 13 (1995) 8-15
2. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
3. Shearer R.J., Davies J.H., Gelister J.S., et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 69 (1992) 521-524
4. Sneller Z.W., Hop W.C., Carpentier P.J., et al. Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study. J Urol 147 (1992) 962-966
5. Whittington R., Broderick G.A., Arger P., et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44 (1999) 1107-1110
6. Yang F.E., Chen G.T., Ray P., et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 33 (1995) 1009-1017
7. Zelefsky M.J., Leibel S.A., Burman C.M., et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29 (1994) 755-761
8. Gleave M.E., Goldenberg S.L., Chin J.L., et al. The Canadian Uro-Oncology Group. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166 (2001) 500-506
9. Kojima M., Ohe H., and Watanabe H. Kinetic analysis of prostatic volume in patients with stage D prostatic cancer treated with LHRH analogues in relation to prognosis. Br J Urol 75 (1995) 492-497
10. Lilleby W., Fossa S.D., Knutsen B.H., et al. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol 57 (2000) 195-200
11. Ohe H., and Watanabe H. Kinetic analysis of prostatic volume in treating prostatic cancer and its predictability for prognosis. Cancer 62 (1988) 2325-2329
12. Okihara K., Watanabe M., Saitoh M., et al. Kinetic analysis of focal hypoechoic lesion in the prostate treated by castration. Prostate 24 (1994) 252-256
13. Padhani A.R., MacVicar A.D., Gapinski C.J., et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218 (2001) 365-374
14. Sanguineti G., Marcenaro M., Franzone P., et al. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol 66 (2003) 151-157
15. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 49 (1997) 38-45
16. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
17. Saitoh M., Ramirez E., and Babaian R.J. Ultrasonic volume monitoring in patient with prostate cancer treated by external beam radiation therapy. Urology 43 (1994) 342-348
18. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
19. Zelefsky M.J., Lyass O., Fuks Z., et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16 (1998) 3380-3385
20. Roeske J.C., Forman J.D., Mesina C.F., et al. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 33 (1995) 1321-1329
21. Herfarth K.K., Pirzkall A., Lohr F., et al. First experiences with a noninvasive patient set-up system for radiotherapy of the prostate. Strahlenther Onkol 176 (2000) 217-222
22. Zellars R.C., Roberson P.L., Strawderman M., et al. Prostate position late in the course of external beam therapy: patterns and predictors. Int J Radiat Oncol Biol Phys 47 (2000) 655-660
23. Antolak J.A., Rosen I.I., Childress C.H., et al. Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys 42 (1998) 661-672
24. Coakley F.V., Kurhanewicz J., Lu Y., et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 (2002) 91-97
25. Eri L.M., Thomassen H., Brennhovd B., and Haheim L.L. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis 5 (2002) 273-278
26. Myschetzky P.S., Suburu R.E., Kelly Jr. B.S., et al. Determination of prostate gland volume by transrectal ultrasound: correlation with radical prostatectomy specimens. Scand J Urol Nephrol 137 (1991) 107-111
27. Sosna J., Rofsky N.M., Gaston S.M., et al. Determinations of prostate volume at 3-Tesla using an external phased array coil: comparison to pathologic specimens. Acad Radiol 10 (2003) 846-853
28. Nathan M.S., Seenivasagam K., Mei O., et al. Transrectal ultrasonography: why are estimates of prostate volume and dimension so inaccurate?. Br J Urol 77 (1996) 401-407
29. Matthews G.J., Motta J., and Fracchia J.A. The accuracy of transrectal ultrasound prostate volume estimation: clinical correlations. J Clin Ultrasound 24 (1996) 501-505
30. Jia G., Baudendistel K.T., von Tengg-Kobligk H., et al. Assessing prostate volume by magnetic resonance imaging: a comparison of different measurement approaches for organ volume analysis. Invest Radiol 40 (2005) 243-248